Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420765 | 1.00 | TAAR1 (0.54) | TAAR1CHRNB2CHRNA4HRH3HRH1 | |
| Hydrochloric Acid SCHEMBL6549764 | 0.82 | HRH1 (0.44) | TAAR1CHRNB2CHRNA4HRH3HRH1 | |
| SCHEMBL6548755 | 0.81 | HRH1 (0.45) | CHRNB2CHRNA4HRH3HRH1LTA4H | |
| SCHEMBL6548752 | 0.81 | HRH1 (0.45) | CHRNB2CHRNA4HRH3HRH1LTA4H | |
| SCHEMBL28355080 | 0.77 | TAAR1 (0.45) | TAAR1SMN1; SMN2KDM4E | |
| SCHEMBL1094428 | 0.77 | HDAC3 (0.41) | TAAR1CHRNB2CHRNA4HRH3LTA4H | |
| SCHEMBL6549844 | 0.76 | HRH2 (0.54) | CHRNB2CHRNA4HRH3HRH1CHRNA7 | |
| SCHEMBL6549840 | 0.76 | HRH2 (0.54) | CHRNB2CHRNA4HRH3HRH1CHRNA7 | |
| Fumaric Acid SCHEMBL7680912 | 0.76 | HRH1 (0.45) | HRH3HRH1ALDH1A1CHRNA7HRH2 | |
| Maleic Acid SCHEMBL7680908 | 0.76 | HRH1 (0.45) | HRH3HRH1ALDH1A1CHRNA7HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145795-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076352-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-04 | — | — | WO | disclosed |
| US-20110224200-A1 | THERAPEUTIC AGENT FOR CHORIORETINAL DEGENERATIVE DISEASE CONTAINING PYRIDINE-3-CARBALDEHYDE 0-(PIPERIDIN-1-YL-PROPYL)-OXIME DERIVATIVE AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| EP-2356988-A1 | THERAPEUTIC AGENT FOR CHORIORETINAL DEGENERATIVE DISEASES COMPRISING PYRIDINE-3-CARBALDEHYDE O-(PIPERIDIN-1-YL-PROPYL)-OXIME DERIVATIVE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145795-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | ADAR, TRDMT1, RNMT | TAAR1 4518/4885CHRNB2 909/4885CHRNA4 1341/4885 |
| US-20110224200-A1 | THERAPEUTIC AGENT FOR CHORIORETINAL DEGENERATIVE DISEASE CONTAINING PYRIDINE-3-CARBALDEHYDE 0-(PIPERIDIN-1-YL-PROPYL)-OXIME DERIVATIVE AS ACTIVE INGREDIENT | ALDH1A2, GRK1, NR2E3 | TAAR1 715/4885CHRNB2 535/4885CHRNA4 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.